6-{[2-(3,4-Dihydroxy-phenyl)ethylamino]-methyl}-2,4-pteridinediamine | 677298-15-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 6-{[2-(3,4-Dihydroxy-phenyl)ethylamino]-methyl}-2,4-pteridinediamine
• 英文别名: 4-[2-[(2,4-diaminopteridin-6-yl)methylamino]ethyl]benzene-1,2-diol
• CAS: 677298-15-6
• 化学式: C₁₅H₁₇N₇O₂
• 分子量: 327.346
• InChiKey: GLUCFIHXMHNBCF-UHFFFAOYSA-N

物化性质

• 沸点：
  683.9±65.0 °C(Predicted)
• 密度：
  1.510±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  156
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  多巴胺 、 氩 、 6-溴乙基-喋啶-2,4-二胺 在 IPr2EtN 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 以22.6%的产率得到6-{[2-(3,4-Dihydroxy-phenyl)ethylamino]-methyl}-2,4-pteridinediamine
  参考文献：
  名称：

  Vasculostatic agents and methods of use thereof

  摘要：

  提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。发明的方法和组合物可用于治疗各种疾病，包括中风、心肌梗死、癌症、缺血/再灌注损伤、类风湿性关节炎等自身免疫疾病、眼部疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥反应、成人/急性呼吸窘迫综合征（ARDS）等。

  公开号：

  US20050282814A1

文献信息

• VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF
  申请人：Wrasidlo Wolfgang

  公开号：US20100278811A1

  公开（公告）日：2010-11-04

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  本发明提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。本发明的方法和组合物可用于治疗各种疾病，例如中风、心肌梗塞、癌症、缺血/再灌注损伤、自身免疫疾病，如类风湿性关节炎、眼部疾病，如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合症、水肿、移植排斥、成人/急性呼吸窘迫综合症（ARDS）等。
• Vasculostatic Agents and Methods of Use Thereof
  申请人：Wrasidlo Wolfgang

  公开号：US20100330030A1

  公开（公告）日：2010-12-30

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  提供用于治疗与血管稳定性受损相关的疾病的组合物和方法。发明的方法和组合物可用于治疗多种疾病，包括中风、心肌梗塞、癌症、缺血/再灌注损伤、自身免疫疾病如类风湿性关节炎、眼部疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥、成人/急性呼吸窘迫综合征（ARDS）等。
• EP1549614A4
  申请人：——

  公开号：EP1549614A4

  公开（公告）日：2008-04-16
• US7208493B2
  申请人：——

  公开号：US7208493B2

  公开（公告）日：2007-04-24
• [EN] VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF<br/>[FR] AGENTS VASCULO-STATIQUES ET PROCEDES D'UTILISATION DE CEUX-CI
  申请人：TARGEGEN INC

  公开号：WO2004030635A2

  公开（公告）日：2004-04-15

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.